Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1319194-13-2

methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1319194-13-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1319194-13-2 Structure

  • Basic information

    1. Product Name: methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate
    2. Synonyms: methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate
    3. CAS NO:1319194-13-2
    4. Molecular Formula:
    5. Molecular Weight: 347.348
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1319194-13-2.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate(CAS DataBase Reference)
    10. NIST Chemistry Reference: methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate(1319194-13-2)
    11. EPA Substance Registry System: methyl 4-((2-(methoxycarbonyl) phenyl) thio)-3-nitrobenzoate(1319194-13-2)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1319194-13-2(Hazardous Substances Data)

1319194-13-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1319194-13-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,9,1,9 and 4 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1319194-13:
(9*1)+(8*3)+(7*1)+(6*9)+(5*1)+(4*9)+(3*4)+(2*1)+(1*3)=152
152 % 10 = 2
So 1319194-13-2 is a valid CAS Registry Number.

1319194-13-2Relevant articles and documents

HEPATITIS B CORE PROTEIN MODULATORS

-

Page/Page column 47; 142; 143, (2018/04/13)

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS

-

Page/Page column 21; 22, (2018/10/19)

The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

HEPATITIS B CORE PROTEIN MODULATORS

-

Paragraph 00076, (2017/04/11)

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

11-OXO-10,11-DIHYDRODIBENZO[B,F][1,4]THIAZEPINE S-OXIDE DERIVATIVES AND THEIR USE AS DOPAMINE D2 RECEPTOR ANTAGONISTS

-

Paragraph 0103, (2015/02/25)

The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

-

Paragraph 00077, (2015/10/05)

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists

Xiao, Jingbo,Free, R. Benjamin,Barnaeva, Elena,Conroy, Jennie L.,Doyle, Trevor,Miller, Brittney,Bryant-Genevier, Marthe,Taylor, Mercedes K.,Hu, Xin,Dulcey, Andrés E.,Southall, Noel,Ferrer, Marc,Titus, Steve,Zheng, Wei,Sibley, David R.,Marugan, Juan J.

, p. 3450 - 3463 (2014/05/20)

The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders. However, clinically approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, especially the D3 DA

Evaluation of NTF1836 as an inhibitor of the mycothiol biosynthetic enzyme MshC in growing and non-replicating Mycobacterium tuberculosis

Newton, Gerald L.,Buchmeier, Nancy,La Clair, James J.,Fahey, Robert C.

experimental part, p. 3956 - 3964 (2011/08/06)

The mycothiol biosynthesis enzyme MshC catalyzes the ligation of cysteine with the pseudodisaccharide GlcN-Ins and has been identified as an essential enzyme in Mycobacterium tuberculosis. We now report on the development of NTF1836 as a micromolar inhibi

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1319194-13-2